Path to Commercialization: Autologous Neural Stem Cell Therapies for Neurodegenerative Diseases
community download

Path to Commercialization: Autologous Neural Stem Cell Therapies for Neurodegenerative Diseases

information we require

please check before submitting



Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Teresa Leezer of RhinoCyte, Inc.   joined us for World Orphan Drug Congress USA 2015 to present about ' Autologous Neural Stem Cell Therapies for Neurodegenerative Diseases'
 
Download the presentation here to understand more about:
  • RhinoCyte key product attributes
  • Investigational New Drug (IND) Submission in Spinal Cord Injury
  • Phase I/II Multi-center Trial 
  • RhinoCyte Financial Status
  • Value Proposition  
...and much more!
 
Get your copy here! 
 
To find out more about how RhinoCyte is working to commercialize autologous neural stem cell therapies for neurodengerative diseases , join us at  World Orphan Drug Congress USA 2016 April 20-22  in Washington, DC.